Search
Results: 6
Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic.
BACKGROUND: Modern designs for dose-finding studies (e.g., model-based designs such as continual reassessment method) have been shown to substantially improve the ability to determine a suitable dose for efficacy testing when...
Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic.
BACKGROUND: Modern designs for dose-finding studies (e.g., model-based designs such as continual reassessment method) have been shown to substantially improve the ability to determine a suitable dose for efficacy testing when...
Accelerating drug development for neuroblastoma
Lucas Moreno, Giuseppe Barone, Steven G DuBois, Jan Molenaar, Matthias Fischer, Johannes Schulte, Angelika Eggert, Gudrun Schleiermacher, Frank Speleman, Louis Chesler, Birgit Geoerger, Michael D Hogarty, Meredith S Irwin, Nick Bird, Guy B Blanchard, Sean Buckland, Hubert Caron, Susan Davis, Bram De Wilde, Hedwig E Deubzer, Emmy Dolman, Martin Eilers, Rani E George, Sally George, Štěrba Jaroslav, John M Maris, Lynley Marshall, Melinda Merchant, Peter Mortimer, Cormac Owens, Anna Philpott, Evon Poon, Jerry W Shay, Roberto Tonelli, Dominique Valteau-Couanet, Gilles Vassal, Julie R Park, Andrew DJ Pearson
Jul 29, 2020
Only one class of targeted agents (anti-GD2 antibodies) has been incorporated into front-line therapy for neuroblastoma since the 1980s. The Neuroblastoma New Drug Development Strategy (NDDS) initiative commenced in 2012 to...
Clinical Trials Drug development epigenetics MYCN Neuroblastoma phase I Preclinical testing Antineoplastic Agents Brain Neoplasms Child Congresses as Topic Drug development Drug Discovery Europe Humans Medical Oncology Molecular Targeted Therapy Neuroblastoma Pediatrics Protein Kinase Inhibitors therapies Investigational
FORWARDS-1
LM Paterson, D Barker, S Cro, P Mozgunov, R Phillips, C Smith, L Nahar, S Paterson, AR Lingford-Hughes
Oct 24, 2022
BACKGROUND: Treatment of opiate addiction with opiate substitution treatment (e.g. methadone) is beneficial. However, some individuals desire or would benefit from abstinence but there are limited options to attenuate problems...
FORWARDS-1
LM Paterson, D Barker, S Cro, P Mozgunov, R Phillips, C Smith, L Nahar, S Paterson, AR Lingford-Hughes
Nov 18, 2022
BACKGROUND: Treatment of opiate addiction with opiate substitution treatment (e.g. methadone) is beneficial. However, some individuals desire or would benefit from abstinence but there are limited options to attenuate problems...
Adaptive Addiction Baclofen Bayesian dependence dose escalation GABA-B Methadone opiate phase I Humans Analgesics Opioid Baclofen Bayes Theorem Carbon Dioxide Cholecalciferol GABA-B Receptor Agonists Hypnotics and Sedatives Methadone Nicotine Opiate substitution treatment Opioid-Related Disorders Single-Blind Method vitamin D